Illumina CEO DeSouza Steps Down Amid Activist Attack, Anti-Trust Battle 6/12/2023

FDA Action Alert: BMS, GSK, Ironwood, Ipsen/Albireo 6/12/2023

FDA Braces for Looming Boom in Cell and Gene Therapy Submissions 6/12/2023

Researchers from the group of Jop Kind developed a new technique called MAbID. This allows them to simultaneously study different mechanisms of gene regulation, which plays a major role in development and disease. MAbID offers new insights into how these mechanisms work together or against each other. The results were published in Nature Methods on the 4th of December.

J&J Expects Up to 6% Growth Next Year with 20-Plus New Drugs by 2030 12/5/2023

CRISPR Reorganizes CAR-T Pipeline Ahead of FDA’s Landmark Decision 12/5/2023

FDA Puts Clinical Hold on Roche BTK Inhibitor Multiple Sclerosis Program 12/5/2023

Roche Gets Phase III Breast Cancer Victory for Inavolisib Combo 12/5/2023

Artificial Intelligence, Part 3: Improving Communication to Impact Patient Behavior 12/5/2023

Alto’s Neuropsychiatric Platform Scores Third Mid-Stage Win 12/5/2023

GSK’s Phase III Meningococcal Vaccine Results Heat Up Race with Pfizer 5/12/2023

Senate Health Committee Seeks to Rein in Drug Prices with Four New Bills 5/12/2023

Sanofi, AstraZeneca Report Promising RSV Pediatric Data Ahead of Pfizer Adcomm 5/12/2023

FDA Advisory Panel Backs ARS Pharma’s Epinephrine Nasal Spray 5/12/2023

Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.

EyePoint Pharma Stock Surges on Phase II Wet AMD-Therapy Results 12/4/2023

Roche Jumps into Lucrative Weight-Loss Space with $2.7B Carmot Buy 12/4/2023

AstraZeneca to Spend $247M in Collaboration with AI Discovery Outfit Absci 12/4/2023

Amgen-Backed Seismic Secures $121M in Series B Funding 12/4/2023

EMA Requests More Data from GLP-1 Drugmakers in Suicidal Ideation, Self-Harm Probe 12/4/2023